Gapping up
In reaction to strong earnings/guidance:
- VERI +10.4% (guides Q2 revs above consensus), HELE +7.7%, SAP +6.2% (provides Q2 update, reaffirms 2020 outlook), PTC +4.8% (guides JunQ revs above consensus), UMC +2.9% (June revs), COST +1.8% (June comps)
Other news:
- APDN +17.5% (forms forms clinical testing subsidiary to maximize utility of FDA EUA-approved Linea COVID-19 assay kit)
- OPTN +16.7% (signs co-promotion agreement with kaléo for XHANCE)
- OSMT +5.3% (receives FDA approval for Upneeq)
- CCL +4.4% (Carnival's AIDA Cruises to restart sailing vacations in August; Bookings for the first short cruises start today)
- CRNX +3.7% (receives orphan drug designation from FDA for Paltusotine for treatment of Acromegaly)
- NKLA +3.5% (Worthington (WOR) disclosed the sale of 5 mln shares of Nikola common stock for ~$238 mln in open market transactions from July 6 to July 7, 2020)
- ERI +2.6% (confirms receipt of approval from the Nevada Gaming Control Board)
- PING +1.9% (upsizes offering and prices 8,977,968 shares of its common stock by certain selling shareholders at $32.00 per share)
- NBL +1.9% (provides second quarter update)
- SAR +1.7% (reinstates quarterly dividend)
- HRZN +1.3% (provides Q2 portfolio update)
- ANAB +0.9% (receives orphan drug designation for imsidolimab)
Analyst comments:
- SIX +5.1% (upgraded to Buy from Neutral at Janney)
- PNR +5% (upgraded to Buy from Underperform at BofA Securities)
- IRT +4.1% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- FFIV +3.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CRWD +2.8% (upgraded to Neutral from Sell at Citigroup)
- ZS +2.6% (upgraded to Buy from Neutral at Citigroup)
- ADSK +2.5% (upgraded to Outperform from Perform at Oppenheimer)
- FTCH +2.5% (upgraded to Buy from Hold at China Renaissance)
- PTSI +2.2% (upgraded to Buy from Hold at Stifel)
- HOG +2% (upgraded to Buy from Neutral at Northcoast)
- NICE +1.8% (upgraded to Buy from Neutral at Citigroup)
- CSCO +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- STZ +1.4% (upgraded to Buy from Hold at Argus)
- BDX +1.3% (upgraded to Overweight from Equal Weight at Barclays)
- REGN +1.2% (upgraded to Buy from Hold at SunTrust)